Mark Avagliano, Chief Business Officer at G1 Therapeutics, Inc. (GTHX), sold 4,081 shares at $2.94 ($13K) on 2024-01-04, disclosed to the SEC on 2024-01-08.
Seasonal sale ($13k) by Chief Business Officer — this insider has traded GTHX in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.12 | 758 | $2K | 18.8% |
| 2 | $3.12 | 2,602 | $8K | 64.4% |
| 3 | $2.94 | 721 | $2K | 16.8% |
| Total | $3.09 avg | 4,081 | $13K | 100% |
| Filing → |
| GTHX | SELL | 2022-01-05 | $15K | — | Filing → |